Literature DB >> 19340500

Potential effects of bisphosphonates on bone ultrastructure.

C Roux1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19340500     DOI： 10.1007/s00198-009-0865-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  11 in total

1.  Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.

Authors:  Ruth Zoehrer; Paul Roschger; Eleftherios P Paschalis; Jochen G Hofstaetter; Erich Durchschlag; Peter Fratzl; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-07       Impact factor: 6.741

2.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.

Authors:  P M Chavassieux; M E Arlot; C Reda; L Wei; A J Yates; P J Meunier
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

3.  Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

Authors:  Erich Durchschlag; Eleftherios P Paschalis; Ruth Zoehrer; Paul Roschger; Peter Fratzl; Robert Recker; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

4.  Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.

Authors:  B Borah; T E Dufresne; E L Ritman; S M Jorgensen; S Liu; P A Chmielewski; R J Phipps; Xiaojie Zhou; J D Sibonga; R T Turner
Journal:  Bone       Date:  2006-03-29       Impact factor: 4.398

5.  Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women.

Authors:  P Roschger; S Rinnerthaler; J Yates; G A Rodan; P Fratzl; K Klaushofer
Journal:  Bone       Date:  2001-08       Impact factor: 4.398

6.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

7.  The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.

Authors:  Babul Borah; Erik L Ritman; Thomas E Dufresne; Steven M Jorgensen; Sheng Liu; Jarek Sacha; Roger J Phipps; Russell T Turner
Journal:  Bone       Date:  2005-07       Impact factor: 4.398

8.  Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

Authors:  R R Recker; R S Weinstein; C H Chesnut; R C Schimmer; P Mahoney; C Hughes; B Bonvoisin; P J Meunier
Journal:  Osteoporos Int       Date:  2004-01-16       Impact factor: 4.507

9.  Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

Authors:  Robert R Recker; Pierre D Delmas; Johan Halse; Ian R Reid; Steven Boonen; Pedro A García-Hernandez; Jerzy Supronik; E Michael Lewiecki; Luis Ochoa; Paul Miller; Huilin Hu; Peter Mesenbrink; Florian Hartl; Juerg Gasser; Erik F Eriksen
Journal:  J Bone Miner Res       Date:  2008-01       Impact factor: 6.741

Review 10.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507
View more
  1 in total

1.  Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.

Authors:  Viviana Ribeiro; Mónica Garcia; Raquel Oliveira; Pedro S Gomes; Bruno Colaço; Maria Helena Fernandes
Journal:  J Cell Mol Med       Date:  2013-10-31       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.